PGE2-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells
暂无分享,去创建一个
[1] P. Kalinski. Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.
[2] K. Odunsi,et al. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. , 2011, Cancer research.
[3] R. Edwards,et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. , 2011, Blood.
[4] Y. Daaka,et al. Aberrant PGE₂ metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. , 2011, International immunopharmacology.
[5] B. Brüne,et al. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2 , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] Xinrong Ma,et al. Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4 , 2011, Cancer Immunology, Immunotherapy.
[7] B. Rini,et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.
[8] G. Lesinski,et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy , 2011, Cancer Immunology, Immunotherapy.
[9] A. Cesario,et al. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. , 2011, Current medicinal chemistry.
[10] W. Fellows-Mayle,et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. , 2011, Cancer research.
[11] D. Gabrilovich,et al. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.
[12] J. D. Di Santo,et al. IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function , 2010, European journal of immunology.
[13] J. Vieweg,et al. Pivotal Advance: Tumor‐mediated induction of myeloid‐derived suppressor cells and M2‐polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells , 2010, Journal of leukocyte biology.
[14] P. Serafini. Editorial: PGE2‐producing MDSC: a role in tumor progression? , 2010, Journal of leukocyte biology.
[15] T. Padhya,et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.
[16] A. Sodhi,et al. Role of prostaglandin E2 in peptidoglycan mediated iNOS expression in mouse peritoneal macrophages in vitro , 2010, FEBS letters.
[17] H. Hoogsteden,et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function , 2010, BMC Cancer.
[18] G. Prendergast,et al. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. , 2010, The American journal of pathology.
[19] S. Ostrand-Rosenberg. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.
[20] V. Bronte,et al. Myeloid-derived suppressor cell heterogeneity and subset definition. , 2010, Current opinion in immunology.
[21] A. Dietz,et al. Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer , 2010, The Prostate.
[22] E. Gorelik,et al. Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes , 2010, Cancer Immunology, Immunotherapy.
[23] C. Divino,et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. , 2010, Cancer research.
[24] M. Lutz,et al. Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development , 2009, European journal of immunology.
[25] V. Bronte. Myeloid‐derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions , 2009, European journal of immunology.
[26] Heather R. Roberts,et al. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. , 2009, Carcinogenesis.
[27] M. Manns,et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.
[28] E. Pilozzi,et al. COX‐2 is induced by HGF stimulation in Met‐positive thyroid papillary carcinoma cells and is involved in tumour invasiveness , 2009, The Journal of pathology.
[29] J. Talmadge,et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. , 2009, International immunopharmacology.
[30] J. Vieweg,et al. Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer , 2009, The Journal of Immunology.
[31] T. Padhya,et al. Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1 , 2009, The Journal of Immunology.
[32] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[33] M. Atkins,et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.
[34] Xuetao Cao,et al. Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.
[35] G. Hur,et al. The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells , 2009, Journal of immunotherapy.
[36] T. Skaar,et al. Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition1 , 2009, The Journal of Immunology.
[37] U. Grohmann,et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis , 2008, Proceedings of the National Academy of Sciences.
[38] Yuan Zhang,et al. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. , 2008, Clinical immunology.
[39] Guang-Xian Zhang,et al. IDO: a double-edged sword for T(H)1/T(H)2 regulation. , 2008, Immunology letters.
[40] Michelle Collazo,et al. Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.
[41] Craig Murdoch,et al. The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.
[42] M. Manns,et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.
[43] I. Borrello,et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.
[44] G. Prendergast. Immune escape as a fundamental trait of cancer: focus on IDO , 2008, Oncogene.
[45] D. Munn,et al. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation , 2008, Proceedings of the National Academy of Sciences.
[46] P. Rodriguez,et al. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives , 2008, Immunological reviews.
[47] G. Prendergast,et al. Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape , 2008, Immunological reviews.
[48] P. De Baetselier,et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.
[49] C. Divino,et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. , 2008, Blood.
[50] Yoshihiko Yamada,et al. Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. , 2008, Oncology reports.
[51] P. Tripathi. Nitric oxide and immune response. , 2007, Indian journal of biochemistry & biophysics.
[52] B. Baban,et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. , 2007, The Journal of clinical investigation.
[53] J. Siegfried,et al. Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non–Small-Cell Lung Cancer , 2007, Molecular Pharmacology.
[54] A. Sacchetti,et al. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[55] S. Albelda,et al. Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response1 , 2007, The Journal of Immunology.
[56] L. Mariani,et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] L. Moldawer,et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis , 2007, The Journal of experimental medicine.
[58] P. Sinha,et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. , 2007, Cancer research.
[59] D. Munn,et al. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.
[60] B. Tóth,et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. , 2007, International immunopharmacology.
[61] P. Rodriguez,et al. Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[62] J. Califano,et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.
[63] Paolo Serafini,et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.
[64] B. Pockaj,et al. Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO1 , 2006, The Journal of Immunology.
[65] C. Chi,et al. Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. , 2006, Cancer letters.
[66] L. Brys,et al. Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer , 2006 .
[67] Yuan Zhang,et al. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. , 2006, Cancer research.
[68] S. Ferrari,et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. , 2006, Blood.
[69] T. Šarić,et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. , 2006, Blood.
[70] U. Grohmann,et al. The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.
[71] D. Besselsen,et al. Short‐term dietary administration of celecoxib enhances the efficacy of tumor lysate‐pulsed dendritic cell vaccines in treating murine breast cancer , 2006, International journal of cancer.
[72] C. Divino,et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.
[73] S. Albelda,et al. Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine , 2006, Clinical Cancer Research.
[74] J. Morrow,et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. , 2006, Cancer research.
[75] P. De Baetselier,et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. , 2006, Blood.
[76] P. Scherle,et al. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.
[77] Hua Yu,et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.
[78] S. Sebti,et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. , 2005, Cancer research.
[79] S. Dubinett,et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.
[80] M. Albert,et al. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. , 2005, Blood.
[81] D. Gabrilovich,et al. Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1 , 2005, The Journal of Immunology.
[82] V. Bronte,et al. Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.
[83] Li Zhu,et al. Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells1 , 2005, The Journal of Immunology.
[84] M. Huang,et al. Cyclooxygenase 2 Inhibition Promotes IFN-γ-Dependent Enhancement of Antitumor Responses1 , 2005, The Journal of Immunology.
[85] J. Regan,et al. Differential Regulation of Phosphorylation of the cAMP Response Element-Binding Protein after Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 , 2005, Molecular Pharmacology.
[86] M. Huang,et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.
[87] D. Gabrilovich,et al. STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion1 , 2005, The Journal of Immunology.
[88] P. Sinha,et al. Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.
[89] M. Huang,et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. , 2005, Journal of immunology.
[90] D. Gabrilovich. Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.
[91] E. Hooghe-Peters,et al. Mechanism of Prostaglandin (PG)E2-Induced Prolactin Expression in Human T Cells: Cooperation of Two PGE2 Receptor Subtypes, E-Prostanoid (EP) 3 and EP4, Via Calcium- and Cyclic Adenosine 5′-Monophosphate-Mediated Signaling Pathways1 , 2004, The Journal of Immunology.
[92] B. Fingleton,et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.
[93] D. Munn,et al. Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.
[94] J. Brayer,et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.
[95] A. V. Timoshenko,et al. PGE2‐mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors , 2004, International journal of cancer.
[96] R. Jove,et al. Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.
[97] J. Ceuppens,et al. Regulation of the immune response by prostaglandins , 1983, Journal of Clinical Immunology.
[98] L. Neckers,et al. IL‐1β mediated up‐regulation of HIF‐lα via an NFkB/COX‐2 pathway identifies HIF‐1 as a critical link between inflammation and oncogenesis , 2003 .
[99] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[100] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[101] D. Gabrilovich,et al. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species , 2003, Journal of leukocyte biology.
[102] J. Ochoa,et al. l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes1 , 2003, The Journal of Immunology.
[103] K. Taskén,et al. Combined Spatial and Enzymatic Regulation of Csk by cAMP and Protein Kinase A Inhibits T Cell Receptor Signaling* , 2003, The Journal of Biological Chemistry.
[104] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[105] J. Regan,et al. Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated Kinases* , 2003, The Journal of Biological Chemistry.
[106] K. Subbaramaiah,et al. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. , 2003, Trends in pharmacological sciences.
[107] M. Colombo,et al. IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.
[108] Yun-Jin Jung,et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[109] Naphtali Abudarham,et al. Prostaglandin E2 Suppresses NK Activity In Vivo and Promotes Postoperative Tumor Metastasis in Rats , 2003, Annals of Surgical Oncology.
[110] Jeonghee Cho,et al. Induction of COX‐2 by LPS in macrophages is regulated by Tpl2‐dependent CREB activation signals , 2002, The EMBO journal.
[111] H. Tai,et al. Prostaglandin catabolizing enzymes. , 2002, Prostaglandins & other lipid mediators.
[112] J. Regan,et al. Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 * , 2002, The Journal of Biological Chemistry.
[113] A. Visintin,et al. Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.
[114] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[115] V. Bronte,et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. , 2001, Journal of immunotherapy.
[116] A. Mancini,et al. Prostaglandin E2 Regulates the Level and Stability of Cyclooxygenase-2 mRNA through Activation of p38 Mitogen-activated Protein Kinase in Interleukin-1β-treated Human Synovial Fibroblasts* , 2001, The Journal of Biological Chemistry.
[117] O. Finn,et al. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.
[118] H. Pauels,et al. Prostaglandins, but not tumor‐derived IL‐10, shut down concomitant tumor‐specific CTL responses during murine plasmacytoma progression , 2001, International journal of cancer.
[119] U. Walter,et al. Activation of cGMP-dependent Protein Kinase Iβ Inhibits Interleukin 2 Release and Proliferation of T Cell Receptor-stimulated Human Peripheral T Cells* , 2001, The Journal of Biological Chemistry.
[120] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[121] R. Ronca,et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.
[122] J. Banchereau,et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.
[123] K. Ozato,et al. Interferon Regulatory Factor (Irf)-1 and Irf-2 Regulate Interferon γ–Dependent Cyclooxygenase 2 Expression , 2000, The Journal of experimental medicine.
[124] V. Kaever,et al. Prostaglandin E2 is variably induced by bacterial superantigens in bovine mononuclear cells and has a regulatory role for the T cell proliferative response. , 2000, Immunobiology.
[125] Milton W. Taylor,et al. Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.
[126] Li Zhu,et al. Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis1 , 2000, The Journal of Immunology.
[127] P. Kalinski,et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. , 1999, Immunology today.
[128] I. Chaudry,et al. Role of protein kinase C in cyclic AMP-mediated suppression of T-lymphocyte activation following burn injury. , 1999, Biochimica et biophysica acta.
[129] M. Choudhry,et al. PGE(2)-mediated inhibition of T cell p59(fyn) is independent of cAMP. , 1999, The American journal of physiology.
[130] P. Hwu,et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. , 1999, Journal of immunology.
[131] D. Munn,et al. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.
[132] M. Zeng,et al. Fas-induced caspase denitrosylation. , 1999, Science.
[133] J. Blay,et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.
[134] D. Carbone,et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.
[135] S. Rosenberg,et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. , 1998, Journal of immunology.
[136] P. Kalinski,et al. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. , 1998, Journal of immunology.
[137] R. Seder,et al. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. , 1998, Journal of immunology.
[138] J. Zweier,et al. Inducible Nitric-oxide Synthase Generates Superoxide from the Reductase Domain* , 1998, The Journal of Biological Chemistry.
[139] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[140] P. Holt,et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. , 1998, Journal of immunology.
[141] S. Uddin,et al. Prostaglandin E2 modulation of p59fyn tyrosine kinase in T lymphocytes during sepsis. , 1998, Journal of immunology.
[142] W. Farrar,et al. Nitric oxide and thiol redox regulation of Janus kinase activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[143] P. Kalinski,et al. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. , 1997, Journal of immunology.
[144] J. Zweier,et al. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[145] M. Runge,et al. Hypoxia Induces Cyclooxygenase-2 via the NF-κB p65 Transcription Factor in Human Vascular Endothelial Cells* , 1997, The Journal of Biological Chemistry.
[146] K. Arai,et al. Signal transduction in Th clones: target of differential modulation by PGE2 may reside downstream of the PKC-dependent pathway. , 1996, Cytokine.
[147] J. Regan,et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. , 1994, Molecular pharmacology.
[148] S. Pollack,et al. Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. , 1993, Journal of immunology.
[149] Y. Sugimoto,et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. , 1993, The Journal of biological chemistry.
[150] M. Young,et al. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasi , 1992, Cancer research.
[151] P. Lala,et al. Prostaglandin E2‐Mediated Inactivation of Various Killer Lineage Cells by Tumor‐Bearing Host Macrophages , 1988, Journal of leukocyte biology.
[152] M. Edelstein,et al. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[153] E. Borden,et al. Induction of Tryptophan Degradation In Vitro and In Vivo: A γ-Interferon-Stimulated Activity , 1986 .
[154] E. Borden,et al. Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. , 1986, Journal of interferon research.
[155] R. Mertelsmann,et al. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. , 1985, Journal of immunology.
[156] R. Herberman,et al. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. , 1983, Journal of immunology.
[157] Bankhurst Ad. The modulation of human natural killer cell activity by prostaglandins. , 1982 .
[158] A. Bankhurst. The modulation of human natural killer cell activity by prostaglandins. , 1982, Journal of clinical & laboratory immunology.